Cardinal Health lost a major contract with UnitedHealth Group’s pharmacy benefits subsidiary OptumRx. Cardinal fell as much as 5.2% in New York trading Monday, the biggest intraday loss since February 1. (Bloomberg)
The Supreme Court declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda’s appeal of a lower court’s ruling against the company, which in 2018 had sued Teva and Apotex in Delaware for patent infringement after they applied to make generic versions of Hetlioz. (Reuters)
The recently launched Test-icles campaign, which was created by Ogilvy Mexico and Ogilvy Health New York in support of the Alba Foundation, encourages men to take a pregnancy test to find out if they have testicular cancer. An Ogilvy-backed campaign’s 40-second ad features a pair of gonads – Tano and Nato – who take a pregnancy test and find out they are negative for testicular cancer. (MM+M)
Biosplice’s osteoarthritis drug failed a Phase 3 clinical trial. This development significantly clouds the drug’s chances of approval and the future of a company that was once valued at $12 billion. (Endpoints News)
STAT News detailed how a scientific slip-up caused a pregnant woman to get an untested treatment for preterm birth. Makena, once the only available treatment to prevent preterm birth, has had its share of controversy. (STAT News)
Click here to view yesterday’s Five things for pharma marketers to know.
